Atopic Dermatitis Treatment Market Size, Share And Global Trend By Drug Class (Corticosteroids, Anti-histamines, Calcineurin inhibitors, Interleukin inhibitors, Topical phosphodiesterase-4, Antibiotics, Others), By Route of Administration (Oral, Topical, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Regional Forecast, 2024-2032

In March 2019, Regeneron Pharmaceuticals, Inc. and Sanofi received approval for Dupixent for the treatment of Atopic Dermatitis in adolescent patients. Atopic dermatitis also referred to as Eczema, is a severe skin condition resulting in dry and itchy skin. In atopic dermatitis, dry and red patches appear on the scalp, cheeks, forehead, and face. Estimates for the prevalence of atopic dermatitis varies. Atopic dermatitis is most common in infants especially in the first year after birth. According to the British Association of Dermatologists, one in every 5 children in the United Kingdom is affected by eczema at some stage.  According to the estimates of the National Institute for Health and Care Excellence, atopic dermatitis affects 1 in every 12 adults in the United Kingdom.

The growth in global atopic dermatitis treatment market is estimated to be driven by the increase in the prevalence of atopic dermatitis and advancements in atopic dermatitis treatment. According to the Asthma and Allergy Foundation of America, approximately 7.3% of individuals suffered from atopic dermatitis in the U.S in the year 2016. Apart from these, the recent key mergers and acquisitions with respect to atopic dermatitis are also expected to fuel the global atopic dermatitis treatment market.

The factor that is projected to restrain the global atopic dermatitis treatment market is the non-curable nature of the disease. Additionally, the stringent regulatory guidelines combined with the introduction of generic treatment methods are anticipated to negatively affect the global atopic dermatitis treatment market.

Key Players Covered

Some of the major companies that are present in the global atopic dermatitis treatment market are Novartis AG, Pfizer Inc., Astellas Phrama Inc., Meda, Bayer AG, Allergan, Regeneron Pharmaceuticals, Inc., and other players.

SEGMENTATION

Corticosteroids are anticipated to register higher share in the segmentation by drug class of global atopic dermatitis market as it is the first line of treatment for the disease.

Key Insights

Overview of the prevalence of atopic dermatitis in key countries

Pipeline analysis

Porter’s five forces analysis

Key mergers and acquisitions

Regional Analysis

The global atopic dermatitis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is anticipated to dominate the global atopic dermatitis market followed by Europe owing to the wider healthcare access and evolved healthcare infrastructure. The global atopic dermatitis treatment market is anticipated to grow in Europe owing to the increase in the prevalence of atopic dermatitis. According to the National Institute for Health and Care Excellence, from 2014 to 2015, there were 895 admissions in England for atopic dermatitis. In the emerging countries of Asia Pacific, the global atopic dermatitis market is projected to grow at a higher CAGR in the forecast period owing to the increasing awareness of atopic dermatitis among the patient pool.

Key Industry Developments

• In 2016, Pfizer Inc. acquired Anacor Pharmaceuticals, Inc., which will strengthen its presence in the dermatology market as well as in global atopic dermatitis treatment market.


• In 2018, Galapagos NV and MorphoSys AG entered into a worldwide agreement with Novartis AG for MOR106, a monoclonal antibody being developed for the treatment of atopic dermatitis.


• In the fiscal year of 2016, Eucrisa developed by Pfizer Inc. was approved by the U.S FDA for the treatment of atopic dermatitis